Bennet Urges FDA To Weigh LDT Framework's Impact On Innovation, Patient Access

April 24, 2015 at 5:12 PM
Sen. Michael Bennet (D-CO) urged FDA to evaluate the effect the agency’s draft framework for laboratory developed tests (LDTs) might have on medical innovation and patient access to in vitro diagnostic services, laying out his concerns in a letter Thursday (April 23). The move comes as the House gears up to unveil a second draft of its 21st Century Cures draft bill, after the first iteration of the legislation broached the subject of LDTs by containing a placeholder for diagnostics...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.